Treatment of FSHD patient-derived muscle cells with β2 agonists considerably inhibited DUX4 expression and antagonized its effects [84]—Atrogin1 and MuRF1 may likely be involved in mediating the amelioration observed here. The gene discussed is DUX4; the disease is facioscapulohumeral muscular dystrophy.